Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.70 |
| ▸ | TP53 | P04637 | 11/20 | 0.70 |
| ▸ | THRB | P10828 | 2/20 | 0.70 |
| ▸ | VDR | P11473 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | XPO1 | O14980 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25009635 | 0.94 | TP53 (0.80) | MAPTTP53THRBVDRSMN1; SMN2 | |
| SCHEMBL25011040 | 0.94 | MAPT (0.72) | MAPTTP53THRBVDRSMN1; SMN2 | |
| SCHEMBL25010454 | 0.88 | TP53 (0.89) | MAPTTP53THRBVDRSMN1; SMN2 | |
| SCHEMBL23416173 | 0.86 | TP53 (0.65) | MAPTTP53THRBVDRSMN1; SMN2 | |
| SCHEMBL25010473 | 0.84 | TP53 (0.63) | MAPTTP53THRBVDRSMN1; SMN2 | |
| SCHEMBL25009644 | 0.83 | TP53 (0.64) | MAPTTP53THRBVDRSMN1; SMN2 | |
| SCHEMBL25011048 | 0.82 | TP53 (1.00) | MAPTTP53THRBVDRSMN1; SMN2 | |
| SCHEMBL25010463 | 0.80 | TP53 (0.72) | MAPTTP53THRBVDRSMN1; SMN2 | |
| SCHEMBL25010093 | 0.79 | TP53 (0.73) | MAPTTP53THRBVDRSMN1; SMN2 | |
| SCHEMBL25009659 | 0.79 | TP53 (0.63) | MAPTTP53THRBVDRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041576-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041576-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | NFKBIA, IKBKB, NFKB2 | MAPT 2111/4885TP53 376/4885THRB 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.